Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05386108
Other study ID # ELA-0121
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 31, 2022
Est. completion date December 2025

Study information

Verified date May 2024
Source Stemline Therapeutics, Inc.
Contact Stemline Trials
Phone 877-332-7961
Email clinicaltrials@menarinistemline.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with with or without brain metastases from ER-positive, HER-2 negative breast cancer. Phase 1b is designed to select the recommended phase 2 dose and will be followed by a phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 106
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient has the signed informed consent form before any study-related activities according to local guidelines. 2. Women or men aged =18 years, at the time of informed consent signature. - Female patients may be either postmenopausal or premenopausal or perimenopausal. Postmenopausal status is defined by: 1. Age =60 years 2. Age <60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) or a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value <40 pg/mL (140 pmol/L) or in postmenopausal ranges per local reference ranges 3. Documentation of prior bilateral oophorectomy, at least 1 month before first dose of trial therapy). 3. Patient must have ER-positive, HER-2 negative tumor status as confirmed by local laboratory testing either from a fresh biopsy or from an archival tissue obtained no more than 2 years prior to signing of the informed consent form. - ER and HER-2 testing must be performed in the following manner: - Documentation of ER positive tumor with = 1% staining by immunohistochemistry (IHC) as defined in the 2010 or 2020 American Society for Clinical Oncology (ASCO) recommendations for ER testing, with or without progesterone receptor (PGR) positivity - HER-2 negative tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2013 or 2018 ASCO recommendations for HER-2 testing 4. Patients receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 7 days prior to baseline and not receiving doses higher than 4 mg of dexamethasone per day or equivalent. 5. Any neurological symptoms of brain metastases must be stable for at least 2 weeks before starting trial therapy. 6. Patient has received prior therapy in the metastatic setting including: - At least one endocrine therapy - Up to two chemotherapy regimens - Up to two prior CDK 4/6 inhibitors, not including abemaciclib - If recurrence was observed while on adjuvant therapy or within 12 months of end of adjuvant therapy, this therapy will be counted as part of required prior therapy for eligibility. - Toxicity from prior therapy must be resolved to National Cancer Institute (NCI) CTCAE version 5.0 Grade =1, with the exception of alopecia and peripheral sensory neuropathy (Grade =2). 7. Patient has documented intra- and/or extra-cranial radiological progression or recurrence while on or after the most recent therapy. 8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of =2 9. Patient has adequate bone marrow and organ function, as defined by the following laboratory values: 1. Absolute neutrophil count (ANC) =1.5 × 109/L 2. Platelets =100 × 109/L 3. Hemoglobin =9.0 g/dL 4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE Grade =1 (if screening assessments are abnormal, these assessments may be repeated up to 2 times; subjects may receive appropriate supplementation or treatment prior to reassessment) 5. Creatinine clearance (per Cockcroft-Gault formula) =50 mL/min 6. Serum albumin =3.0 g/dL (=30 g/L) 7. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0 × ULN. If the patient has liver metastases, ALT and AST =5 × ULN 8. Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is =3.0 × ULN or direct bilirubin = 1.5 × ULN 10. The patient is able and willing to adhere to the study visit schedule and other protocol requirements. 11. For Phase 1b, the presence of brain metastases is allowed but not required for eligibility. In Phase 2, patients must have at least one active and measurable brain metastasis per RECIST version 1.1 - Any of the following qualifies brain metastases as active: 1. Newly diagnosed brain metastasis in patients who never received prior CNS-directed therapy. 2. Newly diagnosed brain metastasis outside any area that was previously subjected to CNS-directed therapy 3. Brain metastases that are progressing in an area that has previously been subjected to CNS-directed therapy - For lesions, including brain metastases, to qualify as measurable, and possibly be selected as target lesions, per RECIST version 1.1 (Appendix C), the longest diameter must be =10 mm by CT or magnetic resonance imaging (MRI). Exclusion Criteria: 1. Immediate CNS-specific treatment is likely to be required, per the treating physician's assessment. 2. Patient has imminent organ failure and/or visceral crisis. 3. Patient has leptomeningeal metastases, defined as having positive CSF cytology or unequivocal radiologic or clinical evidence of leptomeningeal involvement. 4. Breast cancer treatment-naïve patients in the metastatic setting. Patients who experience a recurrence while on adjuvant therapy or within 12 months of end of adjuvant therapy are allowed. 5. Prior therapy with abemaciclib in the metastatic setting. Note: Use of abemaciclib in the adjuvant setting is allowed if the last treatment administration was more than 12 months prior to first recurrence. 6. Prior therapy with elacestrant or other investigational SERDs, or alike agents such as SERMs, SERCANs, CERANs, and PROTACs in the metastatic setting. 7. Patient has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or second primary breast cancer. 8. Currently participating in another breast cancer intervention clinical study. Patients who are being followed for overall survival for another clinical trial with no therapy and study intervention are allowed after the washout period for any prior therapy. 9. Prior anti-cancer or investigational drug treatment within the following windows: - Fulvestrant treatment (last injection) <42 days before first dose of study drug - Any other endocrine therapy <14 days or <5 half-lives, whichever is shorter, before first dose of study drug - Chemotherapy or other anti-cancer therapy <21 days before first dose of study drug - Any investigational anti-cancer drug therapy within <28 days or <5 half lives, whichever is shorter - Bisphosphonates or RANKL inhibitors initiated, or dose changed <1 month prior to first dose of study drug. 10. Radiation therapy (other than CNS directed) within 14 days before the first dose of study drug. 11. Uncontrolled significant active infections - Patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening - Patients known to be HIV+ are allowed as long as they have undetectable viral load at baseline. 12. Major surgery within 4 weeks of starting trial therapy. 13. Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition. 14. Females of childbearing potential who do not agree to use a highly effective non-hormonal method of contraception throughout within 28 days of the first dose of study treatment until 28 days of the last dose of study treatment. Highly effective non-hormonal method of contraception includes any of the following: 1. Intrauterine device (non-hormonal) 2. Total abstinence 3. Bilateral tubal occlusion/ligation 4. Have a vasectomized partner with confirmed azoospermia. 15. Men who do not agree abstain from donating sperm or to use a highly effective barrier contraception (use condoms) during the treatment period and for 120 days thereafter. For subjects (who have not undergone vasectomy) with female partners of childbearing potential, the subject and his partner must, in addition to condoms, use highly effective methods of contraception. 16. Females who are breastfeeding or pregnant. 17. Known intolerance to either study drug or any of the excipients. 18. Patients currently receiving or received any of the following medications prior to first dose of trial therapy: 1. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 21 days prior to initiating trial therapy 2. Herbal preparations/medications These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 21 days prior to initiating trial therapy 3. Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization. 19. Any severe medical or psychiatric condition that in the opinion of the investigator(s) would preclude the patient's participation in a clinical study.

Study Design


Intervention

Drug:
Elacestrant
300 mg, 400 mg
Abemaciclib
100 mg, 150 mg

Locations

Country Name City State
Belgium Antwerp University Hospital Edegem
Belgium Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg Leuven
Belgium Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc Woluwe-Saint-Lambert
France Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie Brest
France Centre de Cancerologie du Grand Montpellier Montpellier
France Hopital de la Pitie Salpetriere Paris
France Centre Hospitalier Universitaire de Poitiers Poitiers
Germany Klinikum Bayreuth GmbH Bayreuth
Germany Universitaetsklinikum Duesseldorf Düsseldorf
Germany Universitätsklinikum Erlangen Erlangen
Germany Clinic Worms gGmbH Worms
Germany Clinic Worms gGmbH Worms Rhineland-Palatinate
Germany Helios Klinikum Wuppertal Wuppertal
Greece National and Capodistrian University of Athens - University General Hospital Attikon Athens
Greece Metropolitan Hospital [Oncology] Piraeus
Greece EUROMEDICA General Clinic of Thessaloniki Thessaloníki
Greece Interbalkan European Medical Center Thessaloníki
Italy AOU Ospedali Riuniti Umberto I-G.M.Lancisi -G.Salesi Ancona
Italy IEO - Istituto Europeo di Oncologia, IRCCS Milano
Italy Ospedale San Gerardo, ASST di Monza, IRCCS Monza
Italy PU A. Gemelli, Università Cattolica del Sacro Cuore Rome
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Ewha Womans University MokDong Hospital Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Bundang Hospital Seoul
Spain University Hospital Reina Sofia Córdoba Andalusia
Spain University Clinical Hospital Virgen de la Arrixaca El Palmar Murcia
Spain Clara Campal Comprehensive Cancer Center (CIOCC) Madrid Community Of Madrid
Spain Hospital Clínico San Carlos Madrid
Spain University Hospital 12 de Octubre Madrid Community Of Madrid
Spain University Hospital Ramon y Cajal Madrid Community Of Madrid
Spain Travesia da Choupana Santiago De Compostela
Turkey Hacettepe University Medical Faculty Ankara
Turkey Memorial Ankara Hastanesi Tibbi Onkoloji Ankara
Turkey Prof. Dr. Suleyman Yalcin Sehir Hastanesi Istanbul
United Kingdom The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool
United Kingdom University College London Hospitals NHS Foundation Trust - University College Hospital (UCH) - Macmillan Cancer Centre London
United Kingdom The Christie NHS Foundation Trust - Medical Oncology Manchester
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Gabrail Cancer Center Canton Ohio
United States Providence Medical Foundation Fullerton California
United States University of Texas MD Anderson Cancer Center Houston Texas
United States California Research Institute Los Angeles California
United States SCRI Oncology Partners Nashville Tennessee
United States Virginia Cancer Institute Norfolk Virginia
United States Carle Cancer Center Urbana Illinois

Sponsors (1)

Lead Sponsor Collaborator
Stemline Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Greece,  Italy,  Korea, Republic of,  Spain,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary RP2D Based on the observed number of dose-limiting toxicities (DLTs) during the first cycle. Dose-limiting toxicity is based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Dose-limiting toxicities will be evaluated during the first cycle (28 days) of treatment in up to 3 cohorts during Phase 1b. A DLT will be defined as any of the toxicities listed in the protocol that are not clearly due to breast cancer or extraneous causes. 1 year
Primary Objective Response Rate Defined as the proportion of patients with a best overall response of either a complete response or partial response per blinded independent central review, per RECIST version 1.1. 3 years
Secondary Intracranial Response Rate per Response Evaluation Criteria in Solid Tumors (RECIST) Defined as the proportion of patients achieving a best overall response of confirmed partial response + complete response, based on intracranial lesions per RECIST version 1.1 and blinded independent central review. 3 years
Secondary Intracranial Response Rate per Response Assessment in Neuro-Oncology (RANO) Defined as the proportion of patients achieving a best overall response of confirmed partial response plus complete response, based on intracranial lesions (per RANO criteria) and per blinded independent central review. 3 years
Secondary Duration of Tumor Response Defined as the duration of time from the date when criteria are met for either a complete response or partial response, per RECIST v1.1, until the first date that progressive disease is objectively documented, per blinded independent central review. 3 years
Secondary Clinical Benefit Rate Defined as the proportion of patients who have the best overall response a complete response, a partial response, or stable disease. 3 years
Secondary Duration of Progression-Free Survival Defined as the time elapsing between the start of treatment and the date of the earliest evidence of objective disease progression or death of any cause before documented disease-progression assessed through study completion. 3 years
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A